Johnson & Johnson surpassed estimates last quarter and has raised its full-year guidance, though sales for its autoimmune medication Stelara plunged.
Revenue was up 9.9% year-over-year to US$24.06 billion, beating LSEG-compiled estimates of $23.6 billion. Adjusted earnings per share dipped 2.5% to $2.70, above estimates of $2.66.
“Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact,” said chair and CEO Joaquin Duato.
“The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe. These advancements have the potential to transform patient outcomes and create sustainable, long-term value for shareholders.”
United States sales increased 8.3% to $13.33 billion, and international sales grew 11.9% to $10.73 billion.
Its Innovative Medicine segment’s revenue rose 11.2% to $15.43 billion, while MedTech revenue was up 7.7% to $8.64 billion.
Growth in Innovative Medicine was largely due to oncology drugs like Darzalex and the acquisition of antipsychotic medication Caplyta, the company said. It took a 920 basis point hit from drugs, including Stelara, however, which saw a 59.7% drop in sales worldwide.
The company’s new full-year guidance includes reported sales of $100.3-101.3 billion, up from its January forecast of $100.0-101.0 billion. It expects adjusted earnings per share of $11.45-11.65, raised from its previous projection of $11.43-11.63.
Johnson & Johnson (NYSE: JNJ) shares closed 0.9% higher at $240.10, and rose a further 0.2% after-hours. Its market capitalisation is $578.31 billion.
